BRIEF—Opdivo takes center stage at ASCO for B-MS

The immuno-oncology asset Opdivo (nivolumab) will be central to the data presented by Bristol-Myers Squibb at this year’s ASCO annual meeting.

There will be Phase I/II results from the CheckMate-040 study evaluating Opdivo alongside Yervoy (ipilimumab) in advanced hepatocellular carcinoma, and of the same combination in advanced melanoma from separate studies.

The US pharma company will also present data on Opdivo and Yervoy in asymptomatic advanced renal cell carcinoma brain metastases.